In an attempt to expand its respiratory portfolio, Merck & Co. has agreed to acquire Cidara Therapeutics for a total equity value of approximately US$9.2 B. Through this strategic takeover, Merck picks up Cidara’s CD388, a long-acting drug-Fc conjugate (DFC) designed to target viral neuraminidase for the prevention of seasonal influenza in adults and adolescents at higher risk of influenza-related complications. The deal provides Merck with a significant opportunity to strengthen and expand its focus on its respiratory disease portfolio as it braces for the looming patent expiration on its blockbuster cancer drug, Keytruda.